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Background: Primary gastrointestinal stromal tumours (GISTs) of the duodenum are rare. The aim of this
study was to review the surgical management of GISTs in this anatomically complex region.
Methods: Retrospective review from January 1999 to August 2011 of patients with primary GISTs of the
duodenum.
Results: Forty-one patients underwent resection of duodenal GISTs. All operations were performed with
intent to cure with negative margins of resection. The most common location of origin was the second
portion of the duodenum. Local excision (n = 19), segmental resection with primary anastomosis (n = 11)
and a pancreatoduodenectomy (n = 11) were performed. Two patients underwent an ampullectomy with
local excision. Peri-operative mortality and overall morbidity were 0 and 12, respectively. Patients with
high-risk GISTs (P = 0.008) and those who underwent a pancreatoduodenectomy (P = 0.021) were at a
greater risk for morbidity. The median follow-up was 18 months. Eight patients developed recurrence.
High-risk GISTs and neoplasms with ulceration had the greatest risk for recurrence (P = 0.017, P = 0.029
respectively). The actuarial 3- and 5-year survivals were 85% and 74%, respectively.
Conclusion: The choice and type of resection depends on the proximity to the ampulla of Vater,
involvement of adjacent organs and the ability to obtain negative margins. The morbidity depends on the
type of procedure for GIST.
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Introduction
Gastrointestinal stromal tumours (GISTs) are the most common
mesenchymal neoplasms of the gastrointestinal tract and can arise
anywhere from the oesophagus to the anus.1,2 The most common
locations of origin for GISTs are the stomach (60%–70%), small
intestine (25%–35%), oesophagus (2%–3%), and rarely in the
colon, rectum or appendix (collectively 5%).3 Duodenal GISTs
account for 6%–21% of all resected GISTs of the small bowel.4 The
operative management and outcomes of duodenal GISTs in
the literature are limited to small case series or case reports.1–3,5–10
The aim of the present study was to address the presentation,
management and surgical outcomes of 41 patients with this gas-
trointestinal neoplasm occurring in a rather rare and anatomically
complex location.
Patients and methods
After approval by the institutional review board, a retrospective
review of the medical records of all patients treated operatively for
duodenal GIST at the Mayo Clinic in Rochester, MN from January
1999 to August 2011 was performed. GISTs incidentally discov-
ered by the pathologist in the duodenum resected for other
pathology were excluded. Clinical presentation, diagnostic evalu-
ation, type of operative procedure, pathological and morphologi-
cal GIST characteristics, pathological risk category (low,
intermediate and high)11 and treatment outcomes were collected
during a detailed chart review. The tumour was classified as low,
intermediate or high risk of malignant potential based on the
established criteria of size and mitotic activity per 50 high power
field (HPF). The neoplasm was low risk if size was no larger than
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2 cm and <5 mitosis/50 HPF, intermediate risk if size was 2–5 cm
with >5 mitosis/50 HPF or >10 cm and no more than 5 mitosis/50
HPF, and high risk if size was >5 cm and >5 mitosis/50 HPF.11
All operations were performed with intent to cure and negative
margins of resection. The margin also included the cut ends of the
pancreatic and bile duct in patients who underwent an ampullec-
tomy when necessary to achieve complete resection. The
follow-up protocol at this institution currently includes a history,
physical examination and imaging every 6 months for 5 years and
then yearly afterwards for low-risk GISTs and every 3–4 months
for 3 years, then every 6 months until 5 years and annually there-
after for high-risk patients including those on tyrosine kinase
inhibitors. Follow-up was until the most recent date of a clinic
visit. Follow-up data were available for all patients until death or
as of August 2011 with a median follow-up of 18 months (range:
12 days to 12 years). The last date of follow-up also included
meaningful clinical correspondence and imaging studies from
physicians of patients who chose to have their follow-up closer to
their place of residence because this institution is a tertiary referral
institution.
Surgical complications were classified according to the Clavien-
Dindo Classification where Grade I is any deviation from the
normal post-operative course, Grade II is those requiring phar-
macological treatment, Grade III are those that require surgical,
endoscopic or radiological intervention with or without general
anaesthesia, Grade IV are those with a life-threatening complica-
tion with single- or multi-organ dysfunction and Grade V is com-
plication resulting in death.12
Medians and ranges are used to express continuous data, unless
specified otherwise. Logistic regression models were used for
binary outcomes; P < 0.05 was considered statistically significant.
Kaplan–Meier methodology and Cox regression analysis were
used to analyse survival outcomes. Statistical analyses were per-
formed using the JMP Statistical package (JMP software, Cary,
NC, USA).
Results
Forty-one patients with duodenal GISTs underwent resection at
this institution over a 12-year period. There were 22 men and 19
women with median age of 59 years (range: 39–79) at the time of
operation. Eleven patients presented with symptoms of fatigue
and 11 patients had a duodenal GIST recognized incidentally on
imaging, such as computed tomography or endoscopic ultra-
sonography, or at the time of an operation for another indication.
The median duration of symptoms was 30 days (range: 1 day to 36
months). A total of 18 patients had a pre-operative evidence of a
clinically important haemorrhage attributed to the duodenal
GIST, 14 of whom required a blood transfusion. The mean blood
haemoglobin concentration initiating transfusion was 6.8 
0.4 g/dl (range 5–9.2 g/dl) and the median transfusion require-
ment for patients with pre-operative GI bleeding was 4 units
(range 1–10 units). Pre-operative diagnostic studies varied and
included an upper endoscopy in 32 patients, computed tomogra-
phy in 30 patients and upper GI series and magnetic resonance
imaging in 1 patient each. The second portion of the duodenum
(n = 26) was the most common location. The median size was
4 cm (range 0.7–17 cm). Eighteen patients underwent an endo-
scopic ultrasonography in addition to the upper endoscopy, 14 of
whom also had a fine needle aspiration (FNA) biopsy of the mass.
Seven of the 14 FNA biopsy results were negative for GIST. The
median size of the tumour for true positive and false negative
pathology results on FNA was 3.2 cm (range: 1–4.5) and 3.2 cm
(range: 1.3–4.3), respectively. Ulceration (n = 18) of the tumour
and submucosal location (n = 18) were the most common gross
pathological features of GIST, followed by exophytic growth (n =
5). Classification of the neoplasm by risk of recurrence included
low risk (n = 27), intermediate risk (n = 5) and high risk (n = 9)
GISTs.11 GISTs in the third portion of the duodenum and those
with ulceration were more likely to present with a pre-operative
haemorrhage (P = 0.028 and P < 0.001, respectively). The clinical
and pathological characteristics of GIST by location in the portion
of duodenum are listed in Table 1.
All patients in this series underwent resection and all resections
were performed with intent to cure. All margins of resection were
confirmed as negative by intra-operative frozen section histopa-
thology. Local excision (n = 19), segmental resection with primary
anastomosis (n = 11) and pancreatoduodenectomy (n = 11) were
performed. Five of the 41 patients underwent laparoscopic resec-
tion, including 1 laparoscopic pancreatoduodenectomy. The
median size of the tumours for local excision, segmental resection
and pancreatoduodenectomy were 2.5 cm (range: 0.5–5.1), 5.4 cm
(range: 1.2–10) and 7 cm (range: 2–17), respectively. The size of
the GIST was a predictor for local excision vs. segmental resection
in the first portion of the duodenum (P < 0.001). One en-bloc
resection of the first portion of the duodenum with an antrectomy
was included under the category of segmental resection (Table 1).
Two patients who underwent local excision also had an ampullec-
tomy. Pancreatico-biliary to duodenal continuity after a septec-
tomy was performed with pancreatico-biliary stenting in each of
these patients. One additional patient had a sphincteroplasty
during a segmental resection extended immediately adjacent to
the ampulla. Two patients had hepatic metastases (6 and 2
metastases each) resected at the time of the initial operation.
There was no peri-operative mortality. The overall morbidity
rate was 29% [Clavien-Dindo class I (n = 2), II (n = 2), IIIa (n = 6),
IIIb (n = 1) and IVa (n = 1)] with severe morbidity (Clavien-
Dindo class  III) in 20%. Severe morbidity included fascial
dehiscence in 1 patient, a pancreatic fistula in 3 (all after pancre-
atoduodenectomy), enteric leak in 2 patients requiring percuta-
neous placement of drains and anastomotic site bleeding
requiring endoscopic intervention in 2. Patients with high-risk
histological characteristics of the GIST are more likely to have
complications when compared with patients in the intermediate-
or low-risk category (OR 8.8: CI 1.7–55.2; P = 0.008). Also,
patients who underwent a pancreatoduodenectomy were more
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likely to develop complications than those who underwent a local
excision or a segmental resection (OR 14.8: CI 2.5–131.3 P =
0.002). One patient who underwent a local excision of the tumour
with sphincteroplasty developed a benign, distal common bile
duct stricture requiring a Roux-en-Y hepaticojejunostomy. Three
patients in the ampullectomy and sphincteroplasty group did not
have any complications.
The median follow-up was 18 months (range: 12 days to 12
years). Two patients received neoadjuvant and 7 patients received
adjuvant therapy with Gleevec® (Imatinib; Novartis Pharmaceu-
tical Corporation, Basel, Switzerland). There have been seven
deaths during the follow-up period; four were related to recur-
rent GISTs, whereas three were unrelated to the disease. There
have been eight recurrences of the GIST, involving six patients in
the high-risk and one each in intermediate- and low-risk groups.
Three of the eight patients with recurrence GISTs underwent
resection of the recurrence, including a metastectomy of a pelvic
recurrence necessitating a hysterectomy/bilateral salpingo-
oophorectomy combined with recto-sigmoidectomy, resection of
the remainder of duodenum with Roux-en-Y reconstruction for
local duodenal recurrence and one with both a local duodenal
recurrence and hepatic metastasis had a local excision and sub-
segmental hepatic resections. Six of the seven patients with
recurrent disease underwent some form of tumour-directed
therapy, including targeted inhibitor therapy in six, surgical
resection in three and radiofrequency ablation of a hepatic
recurrence in one. Most patients had more than one form of
therapy for recurrence. Intervention was discontinued in one
patient who could not tolerate imatinib therapy and whose per-
formance status precluded other interventions. Patients with
ulceration had the greatest risk of recurrence compared with
submucosal or exophytic growth (3-year recurrence-free survival
was 43% vs. 100%; P = 0.031). Those in the pathological high-
risk category were also at an increased risk of recurrence (3-year
recurrence-free survival was 29%, 67% and 90% for the high-,
intermediate- and low-risk pathological category, respectively,
P = 0.017).
The median time to recurrence was 18 months (range: 7 months
to 11 years). There were 15 and 11 patients evaluated at 3- and
5-years, respectively. The 3- and 5-year overall survival was 85%
Table 1 Charasteristics of GIST per location in duodenum
Location (n) D 1 (3) D 2 (26) D 3 (8) D 4 (4)
Age in yearsa 53 (52–58) 58 (39–81) 62 (39–81) 60 (50–81)
Size in cma 5.3 (1–10) 4.5 (0.5–17) 3.3 (1.2–6.5) 6.2 (5–8)
Risk classf 3 26 8 4
Low 2 17 6 2
Intermediate 0 2 2 1
High 1 7 0 1
Operation
Local resection 2 14b 3 0
Pancreatoduodenectomy 0 11 0 0
Segmental resection 1d 1c 5c 4
Morbiditye,f 0 9 1 2
I 0 1 0 0
II 0 1 0 1
IIIa 0 5 1 0
IIIb 0 0 0 1
Iva 0 1 0 0
Presenting symptoms/signsf
Incidental 1 4 3 3
Fatigue 0 8 2 1
Abdominal pain 1 6 2 0
Melena/blood in stools 0 7 1 0
Early satiety 1 1 0 0
aMean (range).
bAmpullectomy in 2 of 14 patients.
cSphincteroplasty in 1 patient in the D2 and D3 group.
dEn block antro-duodenal resection, Bilroth II reconstruction.
eMorbidity per Clavien-Dindo classification.
fNumber of patients.
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and 74%, respectively (Fig. 1a). The 3- and 5-year disease-free
survival was 80% (Fig. 1b). Survival outcomes were not influenced
by type of operation or pathological risk group (P = 0.22 and P =
0.76, respectively). Recurrent disease was associated with decreased
survival (RR 6; 95% CI 1.26–32.66; P = 0.02). Recurrence
accounted for all four disease-related deaths.
Discussion
GISTs are believed to originate from the pluripotent mesenchy-
mal stem cells destined to differentiate into the interstitial cells
of Cajal and are characterized by expression of the transmem-
brane receptor tyrosine kinase c-KIT and the CD 117 antigen.10
GISTs have a predilection for the upper gastrointestinal tract and
when sought have been found as incidental lesions in up to 10%
of pathological specimens resected for other indications.11 An
incidental pre-operative diagnosis of duodenal GIST accounted
for 27% of patients in our study (n = 11); a similar number of
patients had symptoms suggestive of fatigue secondary to
chronic blood loss anaemia. The risk of recurrence for small
bowel GISTs is classified pathologically as low, intermediate or
high based on the number of mitosis per high power field plus
the size of the tumour.13 The greatest chance of disease-free sur-
vival is based on the ability to achieve pathologically negative
margins during the initial operation with clinically localized dis-
ease.9 Comparing size and the mitotic index in various locations
in the gastrointestinal tract, duodenal GISTs appear to have the
greatest risk of recurrence.14 Given the complex anatomy in the
region of the duodenum, resection of a duodenal GIST man-
dates a carefully planned approach depending on the location in
the duodenum and whether the GIST is limited to the anti-
mesenteric vs. the mesenteric border.
Currently the treatment of choice for GIST, regardless of origin,
is local excision with histologically negative margins.11 The low
frequency of local recurrence after limited resections and the local
growth characteristics of GIST do not dictate extended resections.
A GIST arising from the duodenum is more problematic because
of adjacent anatomy. Although large GISTs more frequently
dictate resection of adjacent structures, a small GIST may arise at
organ interfaces or potentiate a desmoplastic reaction which dic-
tates resection of adjacent structures. This finding appears to be
more frequent for duodenal GISTs. Our findings highlight this
issue. GISTs arising in the second and third portion of the duode-
num do not always mandate a pancreatoduodenectomy; indeed,
only 11 of the 26 GISTs in these locations were treated by pancre-
atoduodenectomy. The median size of GIST in this location was
7 cm, and 4 of the 11 patients had a severe desmoplastic reaction.
The goal of resection is to obtain a histopathologically negative
margin. Although size was a significant factor for selection of
operative approach with GISTs arising in the first portion of the
duodenum, proximity to the ampulla of Vater was the most fre-
quent factor affecting operative approach in the second portion of
the duodenum. Negative margins are often achieved with local
excision or segmental resection while preserving the distal bile
duct and pancreatic duct. Involvement of the ampulla may dictate
an ampullectomy with limited resections or pancreatoduodenec-
tomy. Biliary sphincteroplasty with or without septotomy may
also be advantageous to ensure free flow of bile and pancreatic
secretion if resection margins extend to the ampulla. The morbid-
ity of an ampullectomy was less than that of a pancre-
atoduodenectomy (P = 0.018). For a smaller tumour that does not
cause a severe desmoplastic reaction around the pancreatic head
within which malignant extension cannot be excluded, a less inva-
sive but technically challenging pancreas-sparing duodenectomy
may be considered.15
Non-periampullary GISTs or those arising on the anti-
mesenteric border of the duodenum can be addressed by local
excision or a segmental duodenectomy depending on the circum-
ferential extension (Table 1).The defect in the duodenum is usually
closed in a transverse fashion to ensure lumen patency. Another
option for large defects that can cause luminal narrowing after local
resection is an on lay Roux-en-Y jejuno-duodenostomy.7 In the D1,
D3, and D4 segments of the duodenum, a larger neoplasm may be
(a)
(b)
Figure 1 (a) Kaplan–Meier curve for overall survival (in months). (b)
Kaplan–Meier curve for recurrence-free survival (in months)
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resected with a segmental duodenal resection with end-to-end
anastomosis. A lymphadenectomy is not carried out routinely,
because GISTs do not routinely spread to the lymph nodes except in
the rare patient with Carney’s triad.16,17 Large tumours and those
with a severe desmoplastic reaction involving adjacent organs may
need an en bloc resection to ensure negative margins which is the
most important factor in recurrence-free and progression-free
survival.9 Local excision or segmental resections with anastomosis
or Roux reconstructions have low morbidity compared with the
more extensive pancreatoduodenectomy which may prove neces-
sary to achieve negative margins. In the setting of duodenal GIST,
laparoscopic excision with sound oncological principles is feasible.
Long-term outcomes, however, depend on histology, size of the
primary GIST and the presence of metastatic disease at the time of
the initial operation.9 Although these neoplasms may shrink with
neoadjuvant therapy and improved recurrence-free survival has
been demonstrated with adjuvant imatinib therapy,18 the number
of patients undergoing such treatment in the present study was too
few to draw any meaningful conclusions. Another limiting
factor was the retrospective nature of the study and a lack of
randomization given the low incidence of GISTs in this anatomic
location.
Conclusion
The duodenum is an uncommon site for GISTs. When present,
symptoms are usually non-specific and can include fatigue from
occult anaemia or abdominal pain. Asymptomatic duodenal
GISTs also occur. Management is complicated by the location of
the GIST in the second portion of the duodenum in relation to the
pancreaticobiliary confluences. Sound oncological principles of
obtaining negative margins should guide operative management.
The operative procedure is dictated by proximity to or involve-
ment of either the distal biliary tract or extension into the pan-
creatic head and can include local excision, segmental resection,
transduodenal resection with ampullectomy or sphincteroplasty
and a pancreatoduodenectomy. Our data suggest that there may
be a role for operative intervention for recurrence in some
patients. Whether adjuvant therapy for patients with duodenal
GISTs differs from that of other gastrointestinal GISTs could not
be determined from this study.
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